首页> 外文OA文献 >Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys
【2h】

Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys

机译:基于嵌合腺病毒载体的疫苗的单次免疫针对猕猴的猿猴免疫缺陷病毒攻击的保护作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Rare serotype and chimeric recombinant adenovirus (rAd) vectors that evade anti-Ad5 immunity are currently being evaluated as potential vaccine vectors for human immunodeficiency virus type 1 and other pathogens. We have recently reported that a heterologous rAd prime-boost regimen expressing simian immunodeficiency virus (SIV) Gag afforded durable partial immune control of an SIV challenge in rhesus monkeys. However, single-shot immunization may ultimately be preferable for global vaccine delivery. We therefore evaluated the immunogenicity and protective efficacy of a single immunization of chimeric rAd5 hexon hypervariable region 48 (rAd5HVR48) vectors expressing SIV Gag, Pol, Nef, and Env against a homologous SIV challenge in rhesus monkeys. Inclusion of Env resulted in improved control of peak and set point SIV RNA levels following challenge. In contrast, DNA vaccine priming did not further improve the protective efficacy of rAd5HVR48 vectors in this system
机译:目前,正在评估逃避抗Ad5免疫力的罕见血清型和嵌合重组腺病毒(rAd)载体,作为人类1型免疫缺陷病毒和其他病原体的潜在疫苗载体。最近,我们报道了一种表达猿猴免疫缺陷病毒(SIV)Gag的异源rAd初免-加强疗法,可在恒河猴中对SIV攻击提供持久的部分免疫控制。但是,单次免疫最终可能是全球疫苗交付的首选。因此,我们评估了针对恒河猴中同源SIV攻击表达SIV Gag,Pol,Nef和Env的嵌合rAd5六邻体高变区48(rAd5HVR48)载体进行单次免疫的免疫原性和保护效果。挑战后,包含Env可改善对SIV RNA峰值和设定点的控制。相比之下,DNA疫苗引发并未进一步提高rAd5HVR48载体在该系统中的保护效力

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号